Empery Asset Management LP Acquires New Holdings in Xilio Therapeutics, Inc. $XLO

Empery Asset Management LP bought a new stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,183,040 shares of the company’s stock, valued at approximately $757,000. Xilio Therapeutics makes up 0.7% of Empery Asset Management LP’s holdings, making the stock its 16th biggest position. Empery Asset Management LP owned 1.75% of Xilio Therapeutics at the end of the most recent quarter.

Separately, Squarepoint Ops LLC boosted its stake in Xilio Therapeutics by 39.6% during the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock valued at $277,000 after buying an additional 93,338 shares in the last quarter. Institutional investors own 54.29% of the company’s stock.

Analyst Ratings Changes

XLO has been the subject of several research reports. Wall Street Zen cut Xilio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings downgraded Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Xilio Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Xilio Therapeutics Stock Performance

Shares of Xilio Therapeutics stock opened at $7.90 on Thursday. The stock has a 50-day moving average price of $8.25 and a 200 day moving average price of $8.60. The company has a market cap of $51.98 million, a P/E ratio of -2.22 and a beta of -0.12. Xilio Therapeutics, Inc. has a 1 year low of $6.47 and a 1 year high of $12.74.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.08. The firm had revenue of $12.65 million during the quarter, compared to the consensus estimate of $8.52 million. Xilio Therapeutics had a negative return on equity of 151.42% and a negative net margin of 58.52%.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.